A female ProHealth Care executive has alleged in a lawsuit filed in New York federal court that a male executive traumatized her and that she was told she was being sacked while she was on leave for panic attacks.
Debevoise & Plimpton LLP partner Andrew L. Bab helped shepherd a complex deal that made waves in the health care space this year, working with private equity firms TPG Capital and Welsh Carson Anderson & Stowe in a $4.1 billion acquisition of Kindred Healthcare, earning him a spot as one of Law360's 2018 Health MVPs.
Health care-focused real estate investment trust Welltower Inc. said on Tuesday that an affiliate of Qatar’s sovereign wealth fund has acquired $300 million in the company’s common stock.
Lee Memorial Health System said Monday that a patient claiming she was sexually assaulted by a nurse at the Florida hospital should be sanctioned for deleting her Facebook profile during litigation, spoiling evidence the hospital says could have been used in its defense.
The Trump administration published a sweeping health care manifesto Monday that criticized the ubiquity of comprehensive health insurance and recommended a wide-ranging relaxation of state and federal laws in order to strengthen competition and bring down prices.
A D.C. federal judge rebuked the U.S. Justice Department on Monday for trying to speed through the CVS-Aetna merger before he carried out his role in clearing the deal.
An attorney for the billionaire founder of Insys Therapeutics filed documents in Boston federal court Monday to suggest that prosecutors believed a then-suspect who is now cooperating with prosecutors in the company's bribery case was lying to them in a 2016 proffer, but chose not to prosecute him for the lies.
A Texas appellate court has ruled that United Healthcare is time-barred from pursuing more than $6 million worth of emergency room facility fees it paid to a hospital and two affiliated urgent care centers that the insurer claimed weren’t entitled to collect the fees.
A stockholder filed a proposed class action in Delaware Chancery Court claiming antibiotics company Melinta Therapeutics Inc.'s board breached its fiduciary duty by entering into an agreement to sell $75 million of the company’s stock to shareholder Vatera Holdings LLC at a time when the stock value is distressed.
A Florida magistrate judge has recommended trimming a False Claims Act suit accusing a compounding pharmacy and its private equity fund owner of running a $68 million kickback scheme involving medically unnecessary prescriptions for Tricare beneficiaries.
The parents of a baby born with serious brain injuries have urged an Oklahoma federal court to grant their motion for partial summary judgment against a tribal hospital over claims that negligent care resulted in the injuries, arguing that the court should immediately find in their favor on three significant issues.
Two firms leaped ahead of peers based on proceeds from initial public offerings they steered in November, bolstered by blank check companies that generated the largest IPOs in an otherwise quiet month for deals.
Technology-focused medical device maker ResMed said Monday it will acquire a stake in digital therapeutics firm Propeller Health from Safeguard Scientifics in a $225 million deal, with Fenwick & West LLP and DLA Piper guiding the buyer and seller, respectively.
Walmart and three pharmaceutical companies were hit with a proposed class action in Florida federal court Saturday alleging they contributed to the production and sale of contaminated batches of a drug used to treat high blood pressure and diabetes.
A Miami businessman who has been jailed for nearly two and a half years on charges of carrying out a $1 billion health care fraud must remain in custody through his trial early next year, a Florida federal judge ruled Monday, finding no violation of his due process rights.
DLA Piper’s Eric Falkenberry quantifies litigation risk for buyers and sellers in the M&A arena, runs data boot camps for colleagues and helps dream up innovative new analytics tools, earning him a spot on our 2018 list of Data-Driven Lawyers.
Big Data. Statistical Analysis. Insights. Innovation. These data-driven lawyers are making their mark on the legal industry and developing systems and practices that will change the way law is practiced in the 21st century.
The Centers for Medicare & Medicaid Services' implementation of new laboratory payment rates in Medicare could cost an extra $11 billion unnecessarily, the Government Accountability Office said Friday in a report that urged CMS to change course.
The last week has seen HSBC's private bank unit hit with an action from nearly 250 claimants, Dutch bank ABN Amro sue more than a dozen insurers and Aviva's health unit take on the Saudi Arabian embassy and government. Here, Law360 looks at those and other new claims in the U.K.
The Eleventh Circuit has decided that a federal district judge had been right to allow prosecutors to modify a criminal indictment against a Florida doctor who was later convicted of smuggling medical products into the U.S. as part of a health care fraud scheme.
In UnitedHealthcare v. Azar, a D.C. federal court recently determined that it was too easy for Medicare Advantage health plans to be accused of fraud based on erroneous data. Though the court struck down a regulation instructing plans to use "reasonable diligence," plans should not scale back compliance programs, says Michael Kolber of Manatt Phelps & Phillips LLP.
By 2030, it is possible that 75 percent of lawyers practicing in the U.S. will be millennials. A broadened focus on retention and advancement of all young lawyers is therefore a logical step forward but it fails to address another major retention issue that law firms should explore, says Susan Smith Blakely of LegalPerspectives LLC.
Former U.S. Attorney for the District of Idaho Wendy Olson discusses her decades of experience prosecuting white collar crimes and civil rights violations, her work and challenges as U.S. attorney, and her move to private practice.
The outcome of next week's election remains uncertain, but it is possible to predict some of the policy changes and legislative initiatives likely to arise during lame duck and 116th congressional sessions if Democrats regain a majority in the House of Representatives, say Evan Migdail and Melissa Gierach at DLA Piper LLP.
While the SUPPORT Act is largely directed at treatment and prevention, it contains several momentous provisions for companies that manufacture, distribute or dispense opioid medications. Interestingly, the act also imposes significant analytical and reporting hurdles on the U.S. Drug Enforcement Administration, says Jodi Avergun of Cadwalader Wickersham & Taft LLP.
Anthony Thompson’s "Dangerous Leaders: How and Why Lawyers Must Be Taught to Lead" explores the conflict many lawyers face when charged with the responsibility of leadership. The book is an excellent read for all lawyers, says U.S. District Chief Judge Nannette Jolivette Brown of the Eastern District of Louisiana.
The SUPPORT Act, signed into law this week, is Congress' long-anticipated response to the national opioid crisis. The act's wide-ranging provisions take aim at the entire health care continuum, reflecting the breadth of the crisis as well as the collective resolve of Congress to address the challenges, say attorneys at Morgan Lewis & Bockius LLP.
The U.S. Supreme Court's eventual decision in Azar v. Allina Health Services will be important for all hospitals or care providers that participate in Medicare. But it also has the potential — and risk — to become ensnared in much deeper issues about the foundations of administrative law, say Keith Bradley and Sven Collins of Squire Patton Boggs LLP.
Trial lawyers are frequently taught that they should appear invisible during direct examination — that their job is merely to prompt the witness to start speaking. But the most powerful direct examinations are the ones in which the examiner, not the witness, is controlling the pace, say attorneys with Kobre & Kim LLP.
The Centers for Medicare & Medicaid Services last week proposed a rule that would require disclosure of list prices in ads for prescription drugs. However, a number of questions remain regarding the proposed rule's impact, say attorneys at Ropes & Gray LLP.